Google
PROK — PROKIDNEY CORP. (Healthcare >> Biotechnology)
PROK FAQ
What is PROK's ROE?
PROKIDNEY CORP. reports a Return on Equity (ROE) of 7.31%.
What is PROK's dividend yield?
PROKIDNEY CORP. offers a dividend yield of 0.00%.
What is PROK's Deepscope Quality Score?
Deepscope rates PROK's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PROK?
Deepscope's AI Timing Score for PROK is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PROK belong to?
PROKIDNEY CORP. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.67
Price
-0.04
(-2.34%)
Day Change
|
|
|---|
PROK, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.67 |
| PBV / Sector |
2.07 / 4.71
|
| Earning Per Share | -0.23 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.83 M
GREAT
|
| Average 1W Daily Value |
1.61 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:40 |
| Symbol | PROK |
| Name | PROKIDNEY CORP. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 205.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 543.71 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103
Phone: 336 999 7019
Website: https://prokidney.com
Employees: 231
Sector: Healthcare >> Biotechnology
Description: ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
